The Ras Superfamily of Small GTPases: Molecular Switches in Signalling, Traffic, and Disease

lmmol AI Research Collective · Published 2026-06-24 · lmmol:review:PF00071

🧪 lmctl-orchestrated review — written by an orchestrated team of AI agents, grounded in 2,276 papers from lmmol's literature graph. Citations link to their source on PubMed.

1. Overview

The Ras superfamily (Pfam PF00071) comprises small (~21 kDa) guanine-nucleotide-binding proteins that act as binary molecular switches, cycling between an active GTP-bound and an inactive GDP-bound state to control diverse cellular processes ^[1]. The family fans out into functionally distinct branches: Ras proteins govern proliferative signalling, Rho/Rac/Cdc42 proteins remodel the actin cytoskeleton, Rab proteins coordinate vesicular traffic, Ran controls nucleocytoplasmic transport, and the Rheb/mTOR axis links nutrient status to growth. All share a conserved G-domain fold whose topology mirrors that of bacterial elongation factor EF-Tu, with conserved regions dedicated to GTP binding and hydrolysis ^[2]. The switch is governed by guanine-nucleotide exchange factors (GEFs) that load GTP and GTPase-activating proteins (GAPs) that accelerate intrinsic hydrolysis, returning the protein to its off state.

2. Key proteins

The substrate's most heavily studied members span every branch. Rac1 (Ras-related C3 botulinum toxin substrate 1) and RhoA (transforming protein RhoA), together with Cdc42 (cell division control protein 42 homolog), drive actin-based morphology ^[3][4]. The classical Ras isoforms HRas, KRas, and NRas are the canonical proliferative switches and oncoproteins ^[1]. Ran (GTP-binding nuclear protein Ran) provides the directional cue for nuclear export ^[5]. The Rab branch is broadly represented by Rab-11A, Rab-7a, Rab-8A, Rab-5A, Rab-6A, Rab-1A, and Rab-10, alongside the yeast prototypes YPT1 and SEC4, marking distinct compartments of the secretory and endocytic systems ^[6][7][8]. Rheb (GTP-binding protein Rheb) and the Ras-related Rap proteins (the Krev-1/Rap suppressor) round out the growth-control and tumour-suppressor functions of the family ^[9][10].

3. Structural & mechanistic insights

High-resolution crystallography of H-Ras p21 bound to the non-hydrolysable analogue GppNHp resolved the nucleotide and magnesium binding sites in detail and defined the conserved switch regions ^[2]. A 1.35-Å refinement revealed that the catalytically critical residue Gln61 positions a water molecule for in-line nucleophilic attack on the gamma-phosphate, providing a structural mechanism for GTP hydrolysis and explaining why mutations at Gln61 are activating ^[11]. The structure of the Ras-RasGAP complex captured in a transition-state mimic showed that p120GAP supplies an arginine "finger" (Arg789) into the Ras active site to neutralise developing charge, while stabilising switch II so that Gln61 can act; this work explained at atomic resolution why oncogenic Gly12 and Gln61 mutations abolish GAP-stimulated hydrolysis ^[12]. Beyond the catalytic core, membrane targeting depends on C-terminal lipidation: all Ras proteins are polyisoprenylated on Cys186, and a subset are additionally palmitoylated, which enhances membrane avidity and transforming activity ^[13]. Rho-branch switches transmit signals to effector kinases, exemplified by the discovery of Rho-associated kinase (Rho-kinase/ROK) that binds only GTP-RhoA and drives stress-fibre and focal-adhesion formation ^[14][15]. Rac1 also partners with rhoGDI to regulate the phagocyte NADPH oxidase ^[16]. Bacterial toxins exploit these switches directly: Clostridium difficile toxin B glucosylates RhoA at Thr37 to inactivate it and disaggregate the actin cytoskeleton ^[17].

4. Disease & therapeutic relevance

Ras genes were among the first human oncogenes defined, with activation arising from single point mutations that alter the protein without changing expression level ^[18][19][1]. The structural basis is now clear: mutations at Gly12 and Gln61 cripple GAP-stimulated hydrolysis, locking Ras in its active state ^[12]. The family also intersects tumour suppression, as the Rap/Krev-1 protein reverts the transformed phenotype of Ras-transformed cells ^[10]. The Rheb-mTOR axis ties the superfamily to growth-factor and nutrient signalling, where TSC2 acts as the Rheb GAP and Rheb-GTP directly binds and activates the mTOR kinase complex, a node central to tuberous sclerosis ^[9][20]. Rab dysfunction is linked to immunodeficiencies, cancer, and neurological disorders ^[6][21]. The superfamily is also broadly relevant to infection, as a CRISPR screen identified RAB7A as a host factor whose loss sequesters the ACE2 receptor and reduces SARS-CoV-2 entry ^[22].

5. Recent advances

Modern (2017+) work has substantially reshaped the disease genetics and regulation of the superfamily. A major theme is the Parkinson's-disease kinase LRRK2, which phosphorylates a subset of Rab GTPases on a conserved switch-II residue; systematic proteomics identified 14 LRRK2 substrate Rabs and tied phospho-Rab8A/Rab10 to ciliogenesis via RILPL effectors ^[23]. Rab29 (Rab7L1) was shown to recruit LRRK2 to the trans-Golgi network and act as a master regulator of its activation and localisation ^[24], and LRRK2 with its Rab substrates is sequentially targeted to stressed lysosomes to maintain homeostasis ^[25]. Phospho-Rab10 (Thr73) has been developed into a clinically tractable readout of LRRK2 pathway activity in human neutrophils ^[26]. Extending this axis, a RAB32 Ser71Arg variant was identified as a novel autosomal-dominant Parkinson's risk factor that activates LRRK2 kinase, unifying genetically distinct parkinsonism mechanisms ^[27]. On the Ras side, LZTR1 was discovered to be a substrate-adaptor for a CUL3 ubiquitin ligase that ubiquitinates RAS at Lys170 to attenuate membrane association, with disease mutations recapitulating Noonan syndrome ^[28]. Distinct de novo RAC1 missense mutations were shown to cause developmental disorders with opposing micro- and macrocephaly depending on whether they act as dominant-negative or constitutively active alleles ^[29]. Proximity-interaction mapping of 28 Rho-family baits produced ~9,939 high-confidence interactions, systematically charting GEFs, GAPs, and effectors and identifying new components such as GARRE and PLEKHG3 ^[30]. Rab2 was newly established as a HOPS-binding regulator of autophagic and endocytic lysosomal degradation ^[31].

6. Landmark literature

• ^[1] "Ras genes." — the foundational synthesis defining Ras as a proto-oncogene family and binary switch.
• ^[12] "The Ras-RasGAP complex" — structural basis for GTPase activation and its loss in oncogenic mutants (the arginine-finger mechanism).
• ^[11] H-Ras p21 at 1.35 Å — atomic mechanism of GTP hydrolysis via Gln61 and an ordered water.
• ^[6] "Rab GTPases as coordinators of vesicle traffic." — the defining review of the Rab branch.
• ^[9] "Rheb GTPase is a direct target of TSC2 GAP activity" — linking the superfamily to mTOR growth control.

7. Open questions & gaps

The substrate is rich on foundational structure and on the recent LRRK2-Rab axis, but several areas are thin. Most notably, despite the prompt's interest, the substrate contains no paper describing direct KRAS(G12C) covalent inhibitors or their clinical development, so that modern therapeutic milestone cannot be substantiated here and is flagged as a gap. GEF biology is under-represented: GAPs appear (p120GAP, TSC2) but no GEF structure or mechanism is captured beyond proximity-mapping mentions ^[30]. Ran-mediated nuclear transport is represented only by CRM1/NES export ^[5], with import and the RanGTP gradient itself absent. Effector specificity across the >60 Rabs and how individual switches achieve compartmental identity remain incompletely mapped despite cascade models ^[21]. Finally, two recent substrate entries on mitochondrial transport (Armcx1, Miro1/HDAC6) sit at the periphery of the core GTPase-switch topic ^[32][33] and are noted only as Rho-adjacent context rather than central findings.